Dexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More
Quarterly Performance: Dexcom, Inc. reported a 8% year-over-year revenue increase to $1.114 billion for Q4, surpassing analyst expectations, although adjusted EPS of 45 cents fell short of the consensus estimate of 50 cents.
Future Outlook: The company reaffirmed its FY25 guidance with projected revenue of $4.60 billion and aims to enhance global access to its continuous glucose monitoring products following significant investments in sales force expansion and product launches.
Trade with 70% Backtested Accuracy
Analyst Views on EKG
No data
About the author
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen's Q1 2025 Performance: Qiagen N.V. reported a preliminary net sales growth of approximately 5% for Q1 2025, with adjusted EPS guidance raised to at least $0.55, driven by strong demand for its QuantiFERON TB test and QIAstat-Dx testing system.
2025 Outlook and Market Impact: The company anticipates achieving its mid-term target for operating income margin earlier than expected, while also facing potential challenges from U.S. import tariffs; shares rose 3.06% in premarket trading following the announcement.
Dexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More
Quarterly Performance: Dexcom, Inc. reported a 8% year-over-year revenue increase to $1.114 billion for Q4, surpassing analyst expectations, although adjusted EPS of 45 cents fell short of the consensus estimate of 50 cents.
Future Outlook: The company reaffirmed its FY25 guidance with projected revenue of $4.60 billion and aims to enhance global access to its continuous glucose monitoring products following significant investments in sales force expansion and product launches.
Remote Work Vs. Return-To-Office: Can Veeva's Flexibility Outshine JPMorgan's Office Mandate?
Veeva Systems' Remote Work Success: Veeva Systems Inc. has excelled in remote work policies, leading to a high volume of job postings and attractive salaries, while research indicates that companies offering WFH options generally achieve better stock returns and attract quality talent.
Contrasting Approaches to Work Policies: Unlike Veeva, which promotes remote work, firms like JPMorgan Chase face employee backlash over strict return-to-office mandates, highlighting the ongoing debate about the future of work as many employees prefer flexible arrangements.
Why Veeva Systems Shares Are Diving Friday
- Financial Performance: Veeva Systems Inc. reported strong first-quarter FY25 results with a 24% increase in revenue to $650.3 million, surpassing expectations.
- Operating Income and EPS: Adjusted operating income grew by 66% year-over-year to $260.9 million, and adjusted EPS was $1.50, beating the consensus estimate.
- Cash Position: As of April-end, Veeva Systems had $1.20 billion in cash and equivalents along with short-term investments of $3.6 billion.
- Outlook: The company expects slightly lower revenue for the second quarter compared to estimates but reiterated its adjusted EPS and operating income guidance for FY25.
- Stock Performance: VEEV shares were down by 9.21% at $176.02 following the earnings report, impacting ETFs like First Trust Nasdaq Lux Digital Health Solutions ETF EKG and Sterling Capital Focus Equity ETF LCG.
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen's Q1 2025 Performance: Qiagen N.V. reported a preliminary net sales growth of approximately 5% for Q1 2025, with adjusted EPS guidance raised to at least $0.55, driven by strong demand for its QuantiFERON TB test and QIAstat-Dx testing system.
2025 Outlook and Market Impact: The company anticipates achieving its mid-term target for operating income margin earlier than expected, while also facing potential challenges from U.S. import tariffs; shares rose 3.06% in premarket trading following the announcement.
Dexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More
Quarterly Performance: Dexcom, Inc. reported a 8% year-over-year revenue increase to $1.114 billion for Q4, surpassing analyst expectations, although adjusted EPS of 45 cents fell short of the consensus estimate of 50 cents.
Future Outlook: The company reaffirmed its FY25 guidance with projected revenue of $4.60 billion and aims to enhance global access to its continuous glucose monitoring products following significant investments in sales force expansion and product launches.
Remote Work Vs. Return-To-Office: Can Veeva's Flexibility Outshine JPMorgan's Office Mandate?
Veeva Systems' Remote Work Success: Veeva Systems Inc. has excelled in remote work policies, leading to a high volume of job postings and attractive salaries, while research indicates that companies offering WFH options generally achieve better stock returns and attract quality talent.
Contrasting Approaches to Work Policies: Unlike Veeva, which promotes remote work, firms like JPMorgan Chase face employee backlash over strict return-to-office mandates, highlighting the ongoing debate about the future of work as many employees prefer flexible arrangements.
Why Veeva Systems Shares Are Diving Friday
- Financial Performance: Veeva Systems Inc. reported strong first-quarter FY25 results with a 24% increase in revenue to $650.3 million, surpassing expectations.
- Operating Income and EPS: Adjusted operating income grew by 66% year-over-year to $260.9 million, and adjusted EPS was $1.50, beating the consensus estimate.
- Cash Position: As of April-end, Veeva Systems had $1.20 billion in cash and equivalents along with short-term investments of $3.6 billion.
- Outlook: The company expects slightly lower revenue for the second quarter compared to estimates but reiterated its adjusted EPS and operating income guidance for FY25.
- Stock Performance: VEEV shares were down by 9.21% at $176.02 following the earnings report, impacting ETFs like First Trust Nasdaq Lux Digital Health Solutions ETF EKG and Sterling Capital Focus Equity ETF LCG.
